Johnson & Johnson temporarily halts Covid-19 vaccine output: report
NYSE - LSE
| RBGPF | -1.52% | 73.88 | $ | |
| SCU | 0% | 12.72 | $ | |
| SCS | 0.66% | 10.58 | $ | |
| NGG | -0.11% | 72.15 | $ | |
| BCE | -0.95% | 24.2 | $ | |
| RIO | -1.16% | 63.1 | $ | |
| JRI | -0.46% | 13.09 | $ | |
| CMSD | 0.17% | 22.89 | $ | |
| RELX | -1.86% | 52.73 | $ | |
| CMSC | 0.24% | 22.485 | $ | |
| GSK | -0.68% | 37.97 | $ | |
| BCC | 1.94% | 88.14 | $ | |
| AZN | -1.4% | 72.66 | $ | |
| RYCEF | -0.3% | 13.2 | $ | |
| BP | 0.22% | 32.2 | $ | |
| VOD | -0.79% | 11.43 | $ | |
| BTI | -0.71% | 52.25 | $ |
Johnson & Johnson temporarily halts Covid-19 vaccine output: report
Johnson & Johnson has temporarily suspended production at a key plant manufacturing the Covid-19 vaccine, the New York Times reported Tuesday.
The facility in the Dutch city of Leiden halted output late last year, according to the report, which cited people familiar with the decision.
J&J, without confirming or denying the report, said it has continued to fulfill delivery commitments, a company spokesman said.
The factory, which is currently making an experimental vaccine, is expected to resume production of the Covid-19 vaccine again in a "few" months, the Times reported.
J&J currently has "millions of doses of our Covid-19 vaccine in inventory," according to the J&J spokesman.
"We continue to fulfill our contractual obligations in relation to the Covax facility and the African Union," the company spokesman said.
J&J has projected sales of $3 billion to $3.5 billion in 2022 for its Covid-19 vaccine, much less than the $32 billion forecast by Pfizer for the same period.
But the J&J vaccine has been sought after in developing countries because, unlike other options, it does not require transportation at very cold temperatures. Also, the vaccine was originally billed as a single-shot inoculation.
Additional plants are being outfitted to make the vaccine, but production is not expected until late spring, the Times said.
P.Martin--JdCdC
